Market Insights Health Hospitals Inpatient Care

Neoplasm Treatment - China

China

in China, being a major player in the global market segment of Neoplasm Treatment market, is projected to witness significant revenue growth in the coming years.
According to forecasts, the revenue in the Neoplasm Treatment market in China is expected to reach US$49.85bn in 2024.
Moreover, the market is anticipated to display a steady annual growth rate (CAGR 2024-2029) of 6.12%, leading to a market volume of US$67.10bn by 2029.
When compared to other countries, in the United States is projected to generate the highest revenue in the Neoplasm Treatment market, with a staggering amount of US$90.56bn in 2024.
China's booming biotech industry is driving innovation in neoplasm treatment, positioning the country as a global leader in cancer research.

Key regions: India, Japan, United States, United Kingdom, Germany

Market

Region

Region comparison

Currency

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.